Wells Fargo Believes Baxter International (BAX) Won’t Stop Here
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Baxter International (BAX) yesterday. The company’s shares closed yesterday at $81.73, close to its 52-week high of $82.80.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 17.4% and a 73.7% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Shockwave Medical Inc, Stryker Corporation, and Johnson & Johnson.
Currently, the analyst consensus on Baxter International is a Moderate Buy with an average price target of $83.57, which is a 2.3% upside from current levels. In a report issued on June 20, Piper Jaffray also maintained a Buy rating on the stock with a $90 price target.
See today’s analyst top recommended stocks >>
Baxter International’s market cap is currently $41.69B and has a P/E ratio of 27.82. The company has a Price to Book ratio of 5.45.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems; and pharmacy automation, software and services.